Categorized | Stock Profiles

CMXC (Cell MedX Corp.)

Share Button

cmxc logoCell MedX Corp. (CMXC) is an early development stage company who focuses on the research, development, and commercialization of therapeutic products for patients with diabetes by developing technologies to aid in the management of the illness and related complications.

CMXC is at the leading edge of creating devices that will treat chronic and acute conditions for both self-management and clinical care by combining electro-chemical applications and establishing new levels of treatment referred to as cellular medicine. As so, the company has developed its flagship product known as “E-Balance” which will work to:

  • Improve the efficacy of the patient’s existing medication regimes such as accelerating would healing, improvement with glucose control, blood pressure, insulin resistance, and abatement of diabetic neuropathies
  • Enhance the total efficacy of clinical efforts
  • Eliminate or reduce the need for addictive medication in stress syndrome or chronic pain
  • And can be easily administered by professional care or by the patient at home

Currently, CMXC is Conducting its Pilot Trial, with the aid of University of Alberta’s The Metabolomics Innovation Centre, and has recently Received its First Results detailing the two diabetic subjects displayed substantial changes and improvements in the glucose and lipid metabolism.


Symbol: CMXC [ Current PPS: $0.28 Outstanding Shares: 31M Float: 20.9M – a/o April 13, 2015 ]




  • There are approximately 382 million people living with diabetes worldwide however 185 million people remain undiagnosed
  • By 2035, 1 in 10 people or 592 million people will have diabetes.
  • Approximately 316 million people are currently at a high risk for development Type II diabetes.
  • By 2030, global health expenditures to prevent and treat diabetes and related complications is estimated to total $490 billion
  • Nearly 95% of countries spend 5% or more on of their total healthcare budget on diabetes
  • It is currently difficult and sometimes impossible to manage diabetic conditions such as insulin resistance, cell communication, wound healing etc. with chemical-only methods
  • According to Transparency Market Research, the global insulin market is expected to toal $32.24 billion by 2019.


Recent News

  • Additional Results of CMXC’s pilot trial have been announced and detailed their analysis have yielded additional positive insights.


Get Updates on CMXC and other Hot Penny Stocks by Signing Up to our 100% Free Email Newsletter!

This post was written by:

- who has written 2169 posts on StockRockandRoll.

Contact the author

Comments are closed.

© 2021 MJ Capital, LLC | All rights reserved